21 April, 2010
An Avandia safety study called the TIDE trial may be suspended by the FDA over Avandia heart attack risks.
Calls for an Avandia recall have been renewed over concerns that the diabetes drug increases heart risks. In February, a critical Senate report on Avandia was released following a two-year Senate Finance Committee investigation… Continue reading FDA may suspend Avandia safety study, could lead to Avandia recall
Category: Avandia Cardiovascular Risk | Avandia FDA | Avandia News | Avandia Recall | Avandia Safety | Avandia Senate Report23 March, 2010
FDA in Saudi Arabia suspends diabetes drug Avandia
Distribution of Avandia has been suspended for six months by the Saudi Food and Drug Authority (SFDA), linking use of the diabetes drug to adverse cardiovascular effects. A decision has not been made whether a permanent Avandia recall will follow.
“The S FDA Committee… Continue reading Avandia suspended from market by Saudi FDA
Category: Avandia Cardiovascular Risk | Avandia News | Avandia Recall | Avandia Safety | Avandia Side Effects6 March, 2010
Avandia drug company GlaxoSmithKline defends its popular diabetes drug in a 30-page “white paper” released February 24 rejecting a recent Senate Report stating that GSK downplayed the safety risks of their diabetes treatment Avandia. The prescription drug maker attacks the Senate Finance Committee’s January 2010 report on Avandia, claiming it is inaccurate, unbalanced and gives Continue reading Avandia maker GlaxoSmithKline releases "White Paper Response" to Senate Report on Avandia
Category: Avandia FDA | Avandia News | Avandia Recall | Avandia Safety | Avandia Senate Report23 February, 2010
The U.S. Food and Drug Administration is reviewing data on possible heart risks with GlaxoSmithKline diabetes drug Avandia but has not reached any new conclusions. The FDA will hold a public meeting in July 2010 to discuss the risks and benefits of the Avandia, but said in the meantime doctors and patients should continue to use Avandia Continue reading FDA: No new conclusions on Glaxo's Avandia yet
Category: Avandia Cardiovascular Risk | Avandia Lawsuit | Avandia News | Avandia Recall | Avandia Safety23 February, 2010
FDA Report: Take Avandia Off the Market
Two officials from the Food and Drug Administration are recommending that diabetes drug Avandia be pulled from the market because of its potential to harm the heart, the New York Times reports. Agency reports suggest that if every diabetic taking Avandia switched to a different medication, about 500 heart attacks would be averted each month. And in the third quarter of 2009 Continue reading Avandia recall advised by FDA in report
Category: Avandia Recall